Tuesday, July 19, 2022 Early Results from Trial of Variant-Containing COVID-19 mRNA Vaccines as Second Booster COVID-19 NEWS: Protection from illness provided by SARS-CoV-2 vaccines wanes over time and is compounded by emerging virus variants, including Omicron subvariants. Preliminary results, not yet peer-reviewed, from an NIAID-sponsored Phase 2 trial evaluating safety and immunogenicity of SARS-Co-2-variant-containing mRNA vaccines as a second boost found that volunteers who received vaccine containing Omicron BA.1 produced higher levels of antibodies directed at that variant 15 days after vaccination as compared to those who had received the original (prototype) Moderna mRNA vaccine (mRNA-1273). Read the paper: https://www.medrxiv.org/content/10.1101/2022.07.12.22277336v1 National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107